Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib vs Docetaxel in Previously Treated Advanced Gastric Cancer
NCT02409199Phase 3Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in gastric cancer (GC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02409199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02409199.